Phase II trial of the phosphatidyinositol-3 kinase (PLIK) inhibitor buparlisib (BKM120) in recurrent glioblastoma

被引：4
|
作者：
Wen, Patrick Y.
Yung, W. K. Alfred
Mellinghoff, Ingo K.
Ramkissoon, Shakti
Alexander, Brian Michael
Rinne, Mikael L.
Colman, Howard
Omura, Antonio MarcIllo Paduia
DeAngelis, Lisa Marie
Gilbert, Mark R.
De Groot, John Frederick
Cloughesy, Timothy Francis
Chi, Andrew S.
Lee, Eudocia Quant
Nayak, Lakshmi
Batchelor, Tracy
Chang, Susan Marina
Prados, Michael
Reardon, David A.
Ligon, Keith L.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2019
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC
    Tan, Daniel Shao-Weng
    Lim, Kiat Hon
    Tai, Wai Meng
    Ahmad, Aziah
    Pan, Summer
    Ng, Quan Sing
    Ang, Mei-Kim
    Gogna, Apoorva
    Ng, Yuen Li
    Tan, Bien Soo
    Lee, Haur Yueh
    Krisna, Sakktee Sai
    Lau, Dawn P. X.
    Zhong, Liz
    Iyer, Gopal
    Chowbay, Balram
    Lim, Alvin S. T.
    Takano, Angela
    Lim, Wan-Teck
    Tan, Eng-Huat
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma
    Kaley, Thomas J.
    Panageas, Katherine S.
    Mellinghoff, Ingo K.
    Nolan, Craig
    Gavrilovic, Igor T.
    DeAngelis, Lisa M.
    Abrey, Lauren E.
    Holland, Eric C.
    Lassman, Andrew B.
    JOURNAL OF NEURO-ONCOLOGY, 2019, 144 (02) : 403 - 407
  • [33] Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma
    Thomas J. Kaley
    Katherine S. Panageas
    Ingo K. Mellinghoff
    Craig Nolan
    Igor T. Gavrilovic
    Lisa M. DeAngelis
    Lauren E. Abrey
    Eric C. Holland
    Andrew B. Lassman
    Journal of Neuro-Oncology, 2019, 144 : 403 - 407
  • [34] Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group
    Heudel, P-E
    Fabbro, M.
    Roemer-Becuwe, C.
    Kaminsky, M. C.
    Arnaud, A.
    Joly, F.
    Roche-Forestier, S.
    Meunier, J.
    Foa, C.
    You, B.
    Priou, F.
    Tazi, Y.
    Floquet, A.
    Selle, F.
    Berton-Rigaud, D.
    Lesoin, A.
    Kalbacher, E.
    Lortholary, A.
    Favier, L.
    Treilleux, I.
    Ray-Coquard, I.
    BRITISH JOURNAL OF CANCER, 2017, 116 (03) : 303 - 309
  • [35] Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Jordi Rodon
    Irene Braña
    Lillian L Siu
    Maja J De Jonge
    Natasha Homji
    David Mills
    Emmanuelle Di Tomaso
    Celine Sarr
    Lucia Trandafir
    Cristian Massacesi
    Ferry Eskens
    Johanna C Bendell
    Investigational New Drugs, 2014, 32 : 670 - 681
  • [36] Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors
    Ando, Yuichi
    Inada-Inoue, Megumi
    Mitsuma, Ayako
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Suenaga, Naoko
    Sato, Masahiko
    Kakizume, Tomoyuki
    Robson, Matthew
    Quadt, Cornelia
    Doi, Toshihiko
    CANCER SCIENCE, 2014, 105 (03) : 347 - 353
  • [37] Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Rodon, Jordi
    Brana, Irene
    Siu, Lillian L.
    De Jonge, Maja J.
    Homji, Natasha
    Mills, David
    Di Tomaso, Emmanuelle
    Sarr, Celine
    Trandafir, Lucia
    Massacesi, Cristian
    Eskens, Ferry
    Bendell, Johanna C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 670 - 681
  • [38] Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
    B. Pistilli
    T. Pluard
    A. Urruticoechea
    D. Farci
    A. Kong
    T. Bachelot
    S. Chan
    H. S. Han
    G. Jerusalem
    P. Urban
    D. Robinson
    S. L. Mouhaër
    E. D. Tomaso
    C. Massacesi
    C. Saura
    Breast Cancer Research and Treatment, 2018, 168 : 357 - 364
  • [39] Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
    Pistilli, B.
    Pluard, T.
    Urruticoechea, A.
    Farci, D.
    Kong, A.
    Bachelot, T.
    Chan, S.
    Han, H. S.
    Jerusalem, G.
    Urban, P.
    Robinson, D.
    Mouhaer, S. L.
    Tomaso, E. D.
    Massacesi, C.
    Saura, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 357 - 364
  • [40] A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
    Goodwin, Rachel
    Jonker, Derek
    Chen, Eric
    Kennecke, Hagen
    Cabanero, Michael
    Tsao, Ming-Sound
    Vickers, Michael
    Bohemier, Caryn
    Lim, Howard
    Ritter, Heather
    Tu, Dongsheng
    Seymour, Lesley
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1077 - 1084
12345